Results 2,401-2,420 of 26,857 for speaker:David Cullinane

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Health Strategies (9 Nov 2023)

David Cullinane: Last year, the HSE published the national stroke strategy from 2022 to 2027, which I fully supported. It received €4.9 million in funding for 2023. I understand that approximately €1 million worth of posts are unfilled and there are concerns over their funding. For 2024, the national stroke programme requires millions of euro for 75 essential additional posts to safely staff...

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Health Strategies (9 Nov 2023)

David Cullinane: This shows again that it was quite dangerous not to properly fund the health service for next year but also not provide any additional funding for new measures. As I suspected, any additional funding that will come to the national stroke strategy is simply to stand still and is funding for existing levels of service. Some 6,000 people have a stroke every year and 2,000 of them do not get to...

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Health Strategies (9 Nov 2023)

David Cullinane: The reason we tabled the questions the way we did is to cut through all of the spin and essentially lay bare the consequences of a Government that does not properly fund our health services. As Minister for Health, the Minister knows a huge mistake was made in not properly funding the health services even to stand still but what is worse is that if we do not provide new funding each year,...

Written Answers — Department of Health: Health Strategies (9 Nov 2023)

David Cullinane: 13. To ask the Minister for Health the level of additional core expenditure for new developments, excluding funding for carryover and otherwise maintaining existing levels of service, which has been allocated to the national sepsis programme for 2024; and if he will make a statement on the matter. [48901/23]

Written Answers — Department of Health: Community Care (9 Nov 2023)

David Cullinane: 17. To ask the Minister for Health the level of additional core expenditure for new developments, excluding funding for carryover and otherwise maintaining existing levels of service, which has been allocated to primary and community care reform programmes for 2024; and if he will make a statement on the matter. [48902/23]

Written Answers — Department of Health: Health Strategies (9 Nov 2023)

David Cullinane: 21. To ask the Minister for Health the level of additional core expenditure for new developments, excluding funding for carryover and otherwise maintaining existing levels of service, which has been allocated to the National Cancer Strategy for 2024; and if he will make a statement on the matter. [48898/23]

Written Answers — Department of Health: Departmental Expenditure (9 Nov 2023)

David Cullinane: 78. To ask the Minister for Health the level of additional core expenditure for new developments, excluding funding for carryover and otherwise maintaining existing levels of service, which has been allocated to deliver the promised 1,500 rapid-build hospital beds for 2024; and if he will make a statement on the matter. [49087/23]

Written Answers — Department of Health: Departmental Funding (9 Nov 2023)

David Cullinane: 304. To ask the Minister for Health the level of additional core expenditure for new developments, excluding funding for carryover and otherwise maintaining existing levels of service, which has been allocated to developing home support services for 2024; and if he will make a statement on the matter. [48900/23]

Public Health (Tobacco Products and Nicotine Inhaling Products) Bill 2023: Report and Final Stages (8 Nov 2023)

David Cullinane: I move amendment No. 3: In page 27, to delete lines 35 and 36 and substitute the following: "(a) in such a manner and form as may be prescribed by regulations made by the Minister, which shall ensure that, where permitted, communications directed at consumers which include tobacco prices shall list such products in alphabetical order and shall not show any product or price in a manner...

Public Health (Tobacco Products and Nicotine Inhaling Products) Bill 2023: Report and Final Stages (8 Nov 2023)

David Cullinane: No.

Public Health (Tobacco Products and Nicotine Inhaling Products) Bill 2023: Report and Final Stages (8 Nov 2023)

David Cullinane: I did.

Public Health (Tobacco Products and Nicotine Inhaling Products) Bill 2023: Report and Final Stages (8 Nov 2023)

David Cullinane: I certainly do not want to re-enact the drama of that meeting of the Select Committee on Health that I was not at. I had a health appointment that day but my understanding of the confusion was that there was a parallel Bill that was being talked about that the committee was not aware of. There was some discussion about whether it got it. If I understand what the Minister is saying - I was...

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: I too thank the Irish Kidney Association for the support it has given all of us and for the input and advice it has given us. I hope that the Bill is strengthened because of its input. I hope that when the Bill is passed it really does make a difference on a whole range of fronts. Obviously organ donation is really important and it is coincidental that the Irish Kidney Association was...

Public Health (Tobacco Products and Nicotine Inhaling Products) Bill 2023: Report and Final Stages (8 Nov 2023)

David Cullinane: I move amendment No. 1: In page 9, between lines 27 and 28, to insert the following: “Review of operation of Act, Act of 2002 and Act of 2015 9. The Minister shall, within 24 months after the passing of this Act, carry out a review of the operation of this Act, the Act of 2002, and the Act of 2015, to also examine: (a) the regulation of flavouring, packaging, and advertisement...

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: We support all of the amendments. This is an important part of the Bill in terms of the issues that are at the centre of it. We know that the retention of organ parts, against the wishes or knowledge of family members, has been traumatic. So too has the disposal of organ parts without the consent of the family, and in some cases without even the knowledge of the family. These are...

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: That is fine.

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: I move amendment No. 22: In page 43, between lines 24 and 25, to insert the following: “(2) By the substitution of the following regulation for Regulation 25: “25 (1) The HSE shall— (a) keep a record of and publish the annual activities of procurement organisations and transplantation centres, at hospital level, including aggregated numbers of living and...

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: I will press the amendment.

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: I move amendment No. 11: In page 28, to delete lines 20 to 22 and substitute the following: “(b) the removal of the organ for the purpose of transplantation is for therapeutic benefit and no reward has been or is to be given, and there is no other alternative therapeutic method of comparable effectiveness;”.

Human Tissue (Transplantation, Post-Mortem, Anatomical Examination and Public Display) Bill 2022: Report and Final Stages (8 Nov 2023)

David Cullinane: I move amendment No. 13: In page 29, to delete lines 8 to 10 and substitute the following: “(b) the removal of the organ for the purpose of transplantation is for therapeutic benefit and no reward has been or is to be given, and there is no other alternative therapeutic method of comparable effectiveness;”.